Challenges and Opportunities With Oncology Drug Development in China

Clin Pharmacol Ther. 2019 Feb;105(2):363-375. doi: 10.1002/cpt.1017. Epub 2018 Mar 8.

Abstract

Cancer is a growing public health problem in China. Despite the high unmet medical need of patients with cancer in China, oncology drug approvals have historically lagged behind those in the West, mainly the United States and Europe. China is currently undertaking regulatory reforms at a fast pace in order to mitigate this lag.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • China / epidemiology
  • Drug Development*
  • Ethnicity
  • Humans
  • Legislation, Drug
  • Medical Oncology / trends*
  • Neoplasms / drug therapy*
  • Neoplasms / epidemiology

Substances

  • Antineoplastic Agents